Pharma Update
Columvi: Durable remissions achieved in 3L+ DLBCL with fixed-
duration therapy
Efficacy summary
CR rate, n (%) [95% CI]
ORR, n (%) [95% CI]
Pivotal Ph II (NP30179) in 3L+ DLBCL
IRC N=155*
62 (40)
[32.2-48.2]
80 (52)
[43.5-59.7]
Median follow-up, months
18.2 (0-33)
(range)
Ongoing CRs, n/N (%)
42/62 (68)
Median DoCR, months
26.9 (18.4-NE)
(95% CI)
*Intent-to-treat population; CI, confidence interval;
NE, not estimable.
OS Probability (%)
100
80
60
OS landmark analyses by response at EOT
1
40
CR (N=45)
SD/PD (N=57)
20
PR (N=8)
+ Censored
0
T
T
0 3 6
9
12
15 18 21
Time (months)
Roche
COLUMVI
glofitamab
Columvi: Fixed duration and simple dosing
schedule
Glofitamab
C1
C2
C3 C4 C5 C6
C7
C8
C9 C10
C 11 C12
Treatment
stop
Epcoritamab
C1
C2
C3
C4
C5
C6
C7
C8
C9
Q4W until PD
T
24 27 30
Gazyva pretreatment QW
Q2W
Q3W
Q4W dosing
•
•
Clinically meaningful outcomes in highly refractory r/r DLBCL patients with a CR rate of 40% and a median DoCR of 26.9 months following a fixed treatment
Highly durable responses with 70% of patients with a CR at any time remaining in remission at 18 months post-EOT
© Majority of patients (92%, 30/45) with a CR at EOT are alive at 12 months after EOT
• Following step up dosing in C1, glofitamab is administered in a simple Q3W schedule, with fixed treatment duration of 12 cycles (= 8.5 months)
•
Fixed-duration treatments help to avoid long term side effects, are convenient, and generate savings for the healthcare system
Dickinson M, et al. Hematol. Oncol. 2023;41 (S2):144-6; CR=complete response; ORR=overall response rate; DoCR=duration of complete response; Cl=confidence interval; R/R=relapsed refractory; DLBCL-diffuse large B-
cell lymphoma; EOT-end of treatment; CR=Complete response; SD/PD-Stable disease/ Progressive disease; PR=Partial response; C=Cycle
91View entire presentation